In Brief: Knoll/Hokuriku Seiyaku
Executive Summary
Knoll/Hokuriku Seiyaku: Knoll completes acquisition of 51% of the Japanese firm April 8, purchasing 19 mil. shares of Hokuriku stock at $13.46 (1,450 yen) per share for a total price of $255.5 mil. The shares purchased include the 12.25% stake owned by Searle. Knoll intends to keep Hokuriku's management in place for the time being but will integrate the company with Knoll Japan in the medium term. Hokuriku's major product categories include generics, antibiotics, peripheral nervous system and respiratory disease...
You may also be interested in...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Shire Hopes To Sow Future Deals With $50M Venture Fund
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth